10:39 AM EDT, 05/01/2026 (MT Newswires) -- Moderna (MRNA) affirmed its 2026 revenue growth outlook on Friday and reported better-than-expected first-quarter results amid higher COVID vaccine sales.

The company continues to expect full-year revenue to grow 10% on an annual basis. Analysts in a FactSet survey are projecting 2026 revenue of about $2.1 billion.

For the quarter ended March 31, revenue rose to $389 million from $108 million a year earlier, while analysts expected $236.4 million. Net product sales surged to $352 million from $86 million amid higher COVID vaccine sales, boosted by deliveries under long-term strategic partnerships with government entities in international markets.

Moderna posted a quarterly net loss of $3.40 per share, compared with a loss of $2.52 per share a year earlier. The Street's expectation was for a loss of $4.43 per share.

"The Moderna team delivered a great start to the year, driving significant revenue growth and substantial cost reductions building on actions taken in 2025,"Chief Executive Stephane Bancel said in a statement. The company expects several additional approvals around the world this year, including for its seasonal flu vaccine, Bancel said.

The company's stock was down 2.7% in Friday trade. It's up about 50% so far this year.

The full-year revenue growth outlook incorporates potential future declines in COVID vaccination rates, offset by increased penetration of the company's COVID-19 vaccine mNEXSPIKE and revenue from its long-term strategic partnerships, Chief Financial Officer Jamey Mock said during an earnings call, according to a FactSet transcript.

Moderna does not anticipate any material impact from the Middle East conflict on its 2026 outlook, Mock said.

Price: 44.52, Change: -1.42, Percent Change: -3.09